Anesiva’s Adlea gears up for Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Anesiva will conduct two Phase III trials - one in knee replacement and one in bunionectomy surgeries - for its post-surgical pain candidate Adlea, the firm announces Oct. 10. A long-acting, non-opiate analgesic, Adlea is designed to provide pain relief for weeks to months following a single application. Both trials are expected to begin in the first half of 2008. Anesiva CEO John McLaughlin said the firm is also examining Adlea for other indications such as tendonitis and nerve damage...